The DESTINY‐Lung01 and Lung02 studies have confirmed the anti‐tumor activity of Trastuzumab Deruxtecan in patients with HER2‐mutated advanced NSCLC.27, 28. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.